Synthesis, Docking and Biological Evaluation of a Novel Class of Imidazothiazoles as IDO1 Inhibitors
IDO1, a key dioxygenase in tryptophan-kynurenine metabolism, appeared in the last 10 years at the vanguard of druggable targets in cancer therapy due to its well-established role both in immune escape and inflammatory neovascularization. Among the pool of IDO1 inhibitors that have entered clinical t...
Main Authors: | Marta Serafini, Enza Torre, Silvio Aprile, Alberto Massarotti, Silvia Fallarini, Tracey Pirali |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-05-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/24/10/1874 |
Similar Items
-
Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO-1) Inhibitors Based on Ortho-Naphthaquinone-Containing Natural Product
by: Hongchuan Zhao, et al.
Published: (2019-03-01) -
Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
by: Cemil Bilir, M.D., et al.
Published: (2017-07-01) -
TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
by: V. A. Kozlov, et al.
Published: (2017-07-01) -
IDO Expression in Cancer: Different Compartment, Different Functionality?
by: Annabel Meireson, et al.
Published: (2020-09-01) -
Deletion of indoleamine 2,3 dioxygenase (Ido)1 but not Ido2 exacerbates disease symptoms of MOG35-55-induced experimental autoimmune encephalomyelitis
by: Lisa A. Wetzel, et al.
Published: (2020-08-01)